iRhythm Technologies

iRhythm Technologies, Inc. engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, which continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days, and Zio AT, which provides ECG data but also provides physicians with actionable notifications during the wear period. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iRhythm Technologies posts robust Q4 earnings, eyes global expansion

iRhythm Technologies delivered strong financial results, showcasing growth, innovation, and a positive EBITDA in Q4 2022. The company faces challenges in managing expenses and enhancing integration but has opportunities in new product launches, international expansion, and operational improvements.

iRhythm Technologies posts strong Q1 earnings amidst growth opportunities

iRhythm Technologies delivered robust Q1 2023 results with strong revenue growth and strategic advancements, positioning the company for sustainable expansion.
While challenges like legal inquiries and narrow profitability margins exist, the company's focus on innovation, market penetration, and financial stability bodes well for future prospects.
By capitalizing on strengths like positive clinical data, scalable growth strategies, and market opportunities, iRhythm Technologies aims to navigate challenges and drive long-term success.

iRhythm Technologies posts record revenue growth amidst regulatory challenges

iRhythm Technologies reported strong revenue growth and international expansion milestones despite challenges with FDA warning and product launch delays.
The company's focus on innovation, patient compliance, and market penetration presents opportunities for future growth and advocacy for proactive screening.
While facing challenges in product development and regulatory compliance, iRhythm remains financially robust and strategically positioned for continued success.
Navigating through challenges, iRhythm is poised to capitalize on growth opportunities and strengthen its position in the cardiac monitoring market.

iRhythm Technologies reports strong Q3 growth and eyes global expansion

iRhythm Technologies demonstrated strong financial performance in Q3 2023, with revenue growth, improved patient engagement, and market acceptance of Zio monitoring.
While facing challenges such as gross margin pressure and pricing concerns, iRhythm is focused on strategic growth initiatives and cost management for sustainable profitability.
The company is well-positioned to capitalize on opportunities like silent AFib monitoring, market expansion in Japan, and leveraging guidelines for wider screening to drive future growth.
Overall, iRhythm's Q3 results reflect resilience, strategic planning, and a positive outlook for continued success in 2023 and beyond.

iRhythm Technologies surpasses revenue expectations, eyes international expansion for growth

iRhythm Technologies demonstrated robust financial performance in Q4 2023, exceeding revenue guidance and showcasing growth in key operational metrics.
Despite regulatory challenges and external factors impacting revenue, the company's strategic strengths in product adoption and clinical evidence position it well for future growth.
Opportunities in AI, proactive screening, international expansion, and market disruption present avenues for continued expansion and market leadership.
Balancing challenges with opportunities, iRhythm aims to maintain financial sustainability while driving growth and innovation in the cardiac monitoring space.

iRhythm Technologies reports strong Q1 earnings, eyes global expansion

iRhythm Technologies delivered robust financial performance in Q1 2024, showcasing revenue growth, strategic partnerships, and a focus on sustainable operating leverage improvements.
While facing challenges such as awaiting FDA clearances and managing short-term financial losses, the company remains well-positioned with a strong financial foundation and global growth prospects.
Opportunities lie in upcoming product launches, market expansions, and the exploration of new adjacencies, positioning iRhythm for continued growth and market leadership.
Overall, iRhythm's emphasis on innovation, market expansion, and operational efficiency sets a positive trajectory for future success and shareholder value creation.

iRhythm Technologies excels in Q2 earnings, eyes global expansion

iRhythm Technologies delivered strong financial performance in Q2 2024, driven by product excellence and market expansion efforts.
While facing challenges with compliance and leadership transitions, the company remains focused on growth and operational effectiveness.
Strategic initiatives in primary care, new markets, and product launches position iRhythm well for future success and revenue growth.

iRhythm Technologies reports robust Q3 growth amidst regulatory advancements

iRhythm Technologies showed strong growth and strategic advancements in Q3 2024, focusing on global expansion and product innovation.
While facing financial challenges and regulatory hurdles, the company is actively addressing quality issues and investing in future growth.
Opportunities in international markets, product development, and financial optimization position iRhythm for long-term success and market leadership.
Investors should monitor iRhythm's progress in addressing challenges and capitalizing on growth opportunities for sustainable value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Match Group

Snowflake

Sands Capital Management recently disclosed its portfolio updates for the third quarter of 2020, which ended on Sept. 30.

Top 3rd-Quarter Buys of Frank Sands' Firm

SAN FRANCISCO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study.

Zio by iRhythm Detects Previously Undiagnosed Atrial Fibrillation and Helps to Prevent Hospitalizations, Stroke, and Death as a Result

American Well Corporation

Castlight Health

Global X Telemedicine & Digital Health ETF

GoodRx Holdings

Humana

Teladoc

Telehealth stocks have come to prominence in 2020 for obvious reasons. Read on for those that are positioned to thrive moving forward.

7 Telehealth Stocks To Buy Ahead Of Flu Season

iRhythm to Host Webcast to Discuss Outcomes on Monday, November 16, 2020 iRhythm to Host Webcast to Discuss Outcomes on Monday, November 16, 2020

iRhythm Technologies Announces Data from mSToPS Clinical Trial to be Presented in a Late-Breaking Scientific Session at American Heart Association 2020

M3 Inc

Nuance Communications

There are no silver linings to the pandemic. Nevertheless, some stocks and sectors have benefited greatly from the societal changes COVID-19 has wrought.

5 Telehealth Stocks for Long-Term Financial Fitness

iRhythm Technologies, Inc. (IRTC) CEO Kevin King on Q3 2020 Results - Earnings Call Transcript

iRhythm has key differentiators that insulate the company from peers and provide additional value to the clinical setting, backed by AI software and over 30 clinical studies. Shareholders have enjoyed over 250% in returns over the single-year period, with most upside seen on the back of new CPT-1 codes and physician fee scheduling.

iRhythm Remains Insulated From Peers, Double-Digit Growth By 2021 Is Likely

SAN FRANCISCO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the third quarter 2020 after the close of trading on Thursday, November 5, 2020. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

iRhythm Technologies to Report Third Quarter 2020 Financial Results on November 5, 2020

Alarm.com

Avalara Inc

Etsy

National Vision Hlds

Five9

Freshpet

Lumentum Holdings

Mimecast

Natera

Palomar

Q2 Hld

Silk Road Medical Inc

SPS Commerce

For this report, we analyzed the portfolios of the 13 small-cap growth investment managers with the best 10-year performance records.

Positions In The Portfolios Of The Best-Performing Small-Cap Growth Funds

Roundhill Sports Betting & iGaming ETF

DraftKings

Penn Entertainment

We highlight the first sports betting ETF and a digital health ETF

Most Interesting New ETFs: Sports Betting & Telemedicine

Company selected from over 500 applicants in first-of-its-kind Digital Health Technologies Pilot Company selected from over 500 applicants in first-of-its-kind Digital Health Technologies Pilot

iRhythm Technologies Announces NHS Funding After Winning Artificial Intelligence in Health and Care Award

SAN FRANCISCO, Sept.  01, 2020  (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming 18th Annual Morgan Stanley Global Healthcare Conference.

iRhythm Technologies to Present at the 18th Annual Morgan Stanley Global Healthcare Conference

SAN FRANCISCO, Aug.  21, 2020  (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today the closing of its underwritten public offering of 1,257,142 shares of its common stock at a public offering price of $175.00 per share, which included the exercise in full of the underwriters’ option to purchase 163,975 additional shares of common stock on the same terms and conditions. All of the shares were offered for sale by iRhythm Technologies. Gross proceeds from the offering to iRhythm Technologies were approximately $220 million, before deducting underwriting discounts and commissions and other offering expenses payable by iRhythm Technologies.

iRhythm Technologies Announces Closing of Follow-on Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO, Aug.  18, 2020  (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today the pricing of its underwritten public offering of 1,093,167 shares of its common stock at a public offering price of $175.00 per share, before deducting underwriting discounts and commissions. All of the shares are being offered for sale by iRhythm Technologies. In addition, iRhythm Technologies has granted the underwriters a 30-day option to purchase up to an additional 163,975 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by iRhythm Technologies, are expected to be $191.3 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on August 21, 2020, subject to customary closing conditions.

iRhythm Technologies Announces Pricing of Upsized Public Offering of Common Stock

SAN FRANCISCO, Aug.  18, 2020  (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today that it has commenced an underwritten public offering of 1,000,000 shares of its common stock. All of the shares in the offering are being offered for sale by iRhythm Technologies. In addition, iRhythm Technologies expects to grant the underwriters a 30-day option to purchase an additional 150,000 shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

iRhythm Technologies Announces Proposed Public Offering of Common Stock

iRhythm (IRTC) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

iRhythm (IRTC) Looks Good: Stock Adds 9.6% in Session

iRhythm Technologies, Inc. (IRTC) CEO Kevin King on Q2 2020 Results - Earnings Call Transcript

Cardlytics

Everbridge

Fox Factory Hld

Goosehead Insurance

Howard Hughes

Newmark Group

STAG Industrial

Trex

Technical analyst Jonathan Krinsky believes small-cap stocks could benefit from a rotation out of large-cap techs. Here are 10 to consider.

10 Small-Cap Stocks Ready to Become Large Caps

SAN FRANCISCO, Aug.  06, 2020  (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by iRhythm Technologies, Inc. (NASDAQ: IRTC), please note that in the table of Condensed Consolidated Statements of Operations, the rows for "Net loss per common share, basic and diluted" and "Weighted-average shares, basic and diluted" were missing. The corrected release follows:

iRhythm Technologies Announces Second Quarter 2020 Financial Results

SAN FRANCISCO, Aug.  04, 2020  (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, commented on the recently released Centers for Medicare and Medicaid Services (“CMS”) Calendar Year 2021 Medicare Physician Fee Schedule Proposed Rule (“the Proposed Rule”).  The Proposed Rule and accompanying Addenda were released on August 3, 2020 and August 4, 2020 and update payment policies, payment rates, and other provisions for services furnished under the Medicare Physician Fee Schedule (“PFS”) on or after January 1, 2021.  The Proposed Rule release is followed by a public comment period that will close on October 5, 2020 and will culminate in CMS' release of the Final Rule, which is expected to be announced on or around December 1, 2020 for implementation on January 1, 2021.  The Proposed Rule is therefore subject to change.

iRhythm Technologies Comments on the Centers for Medicare and Medicaid Services 2021 Proposed Medicare Physician Fee Schedule

Conference Call and Webcast Scheduled for August 4, 2020 at 1:10 pm PT/4:10 pm ET Conference Call and Webcast Scheduled for August 4, 2020 at 1:10 pm PT/4:10 pm ET

iRhythm Technologies to Provide Commentary on the Centers for Medicare and Medicaid Services 2021 Proposed Physician Fee Schedule

SAN FRANCISCO, Aug.  04, 2020  (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, commented on the recently released Centers for Medicare and Medicaid Services (“CMS”) Calendar Year 2021 Medicare Physician Fee Schedule Proposed Rule (the “Proposed Rule”). The Proposed Rule was released on August 3, 2020 and updates payment policies, payment rates, and other provisions for services furnished under the Medicare Physician Fee Schedule (“PFS”) on or after January 1, 2021. The Proposed Rule release is followed by a public comment period which will culminate in CMS' release of the Final Rule, which is expected to be announced by December 1, 2020 for implementation on January 1, 2021. The Proposed Rule is therefore subject to change.

iRhythm Technologies Comments on the Centers for Medicare and Medicaid Services 2021 Proposed Physician Fee Schedule

IRHYTHM TECH (IRTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IRHYTHM TECH (IRTC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

SAN FRANCISCO, July  29, 2020  (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming 40th Annual Canaccord Genuity Global Growth Conference in Boston, MA.

iRhythm Technologies to Present at the 40th Annual Canaccord Genuity Global Growth Conference

SAN FRANCISCO, July  21, 2020  (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the second quarter 2020 after the close of trading on Thursday, August 6, 2020. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

News for iRhythm Technologies Stock (IRTC)